Technetium-99m benzimidazolyl iminodiacetic acid hepatobiliary radiopharmaceuticals: structure biodistribution studies.
The biodistribution of fifteen structural variants of the hepatobiliary radiopharmaceutical, technetium-99m benzimidazolyl iminodiacetic acid (BIMIDA) were determined 1 h after i.v. injection into rats. The best compounds with respect to hepatobiliary excretion were those with halogen substituents in the benzene ring of the BIMIDA ligand. The cholescintigraphic properties of the BIMIDA compounds compared favourably with those of technetium-99m acetanilido iminodiacetic acid (HIDA) radiopharmaceuticals.
D000818:Animals; D001659:Biliary Tract / Q000000981:diagnostic imaging*; D007098:Imino Acids / Q000378:metabolism; D008099:Liver / Q000000981:diagnostic imaging*; D015609:Organotechnetium Compounds; D011817:Rabbits; D011877:Radionuclide Imaging; D051381:Rats; D013329:Structure-Activity Relationship; D013667:Technetium / Q000378:metabolism; D014018:Tissue Distribution
D007098:Imino Acids; D015609:Organotechnetium Compounds; C044973:technetium Tc 99m benzimidazolyl iminodiacetic acid; D013667:Technetium